Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2011-01-04
2011-01-04
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C514S015800, C530S328000, C530S387900
Reexamination Certificate
active
07862815
ABSTRACT:
The present disclosure concerns the use of peptides and compositions, such as pharmaceutical compositions, to influence angiogenesis. Particular methods are useful for promoting angiogenesis, while others are particularly useful for inhibiting angiogenesis.
REFERENCES:
patent: 5639855 (1997-06-01), Kitamura et al.
patent: 5830703 (1998-11-01), Kitamura et al.
patent: 5831004 (1998-11-01), Campbell et al.
patent: 5837823 (1998-11-01), Kitamura et al.
patent: 5910416 (1999-06-01), Kitamura et al.
patent: 6117869 (2000-09-01), Picard et al.
patent: 6133304 (2000-10-01), Peterson, Jr. et al.
patent: 6265432 (2001-07-01), Purchase, Jr. et al.
patent: 6307101 (2001-10-01), Campbell et al.
patent: 6320022 (2001-11-01), Cutitta et al.
patent: 6339160 (2002-01-01), Politi et al.
patent: 6350885 (2002-02-01), O'Brien et al.
patent: 6440421 (2002-08-01), Cornish et al.
patent: 2002/0055615 (2002-05-01), Cuttitta et al.
patent: 0 845 036 (1999-06-01), None
patent: 0 926 238 (2000-11-01), None
patent: 0 926 238 (2000-11-01), None
patent: WO 97/07214 (1997-02-01), None
patent: WO 00/69900 (2000-11-01), None
patent: WO 01/18550 (2001-03-01), None
patent: WO 2004/032708 (2004-04-01), None
Belloni et al., “Proadrenomedullin N-Terminal 20 Peptide (PAMP), Acting Through PAMP(12-20)-Sensitive Receptors, Inhibits Ca2+-Dependent, Agonist-Stimulated Secretion of Human Adrenal Glands,”Hypertension33:1185-1189 (1999).
Calvo et al., “Adrenomedullin and proadrenomedullin N-terminal 20 peptide in the normal prostate and in prostate carcinoma,”Microsc. Res. Tech.57(2):98-104 (Apr. 2002)Abstract Only.
Champion et al., “Proadrenomedullin NH2-terminal 20 peptide has direct vasodilator activity in the cat,”Am J. Physiol. 272(4 Pt 2):R1047-54 (Apr. 1997)Abstract Only.
Champion et al., “Structure-activity relationships of adrenomedullin in the circulation and adrenal gland,”Regul. Peptides85(1):1-8 (Nov. 30, 1999)Abstract Only.
Champion et al., “Tone-dependent vasodilator responses to proadrenomedullin NH2-terminal 20 peptide in the hindquarters vascular bed of the rat,”Peptides18(4):513-519 (1997)Abstract Only.
Corcoran et al., “MMP-2: Expression, Activation and Inhibition,”Enzyme Protein49:7-19 (1996).
Corti et al., “Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease,”Cardiovascular Drugs104:1856-1862 (Oct. 9, 2001).
Eto et al., “Adrenomedullin and proadrenomedullin N-terminal 20 peptide: vasodilatory peptides with multiple cardiovascular and endocrine actions,”Trends in Endo and Metab. 12(3):91-93 (Apr. 1, 2001)Abstract Only.
Fernandez-Patron, “Vascular Matrix Metalloproteinase-2-Dependent Cleavage of Calcionin Gene-Related Peptide Promotes Vasoconstriction,”Circ Res. 87:670-676 (2000).
Fry et al., “Proadrenomedullin NH2-terminal peptide (PAMP) (12-20) has vasodepressor activity in the rat and cat,”Life Science60(10):PL161-167 (1997)Abstract Only.
Giannelli and Antonaci, “Gelantinases and their inhibitors in tumor metastasis: form biological research to medical applications,”Histol Histopathol17:339-345 (2002).
Ginda et al., “Decrease of TSH Levels and Epithelium/Colloid Ratio in Rat Thyroid Glands Following Administration of Proadrenomedullin N-Terminal Peptide (12-20),”Horm. Metab. Res., 32:10-14, 2000.
Goffin et al., “Human Endometrial Epithelial Cells Modulate the Activation of Gelatinase A by Stromal Cells,”Gynecol Obstet Invest53:105-111 (2002).
Ishimitsu et al. “Genomic structure of human adrenomedullin gene,”Biochem Biophys Res Commun203(1):631-639 (Aug. 30, 1994)Abstract Only.
Kangawa et al., “Adrenomedullin: a new hypotensive peptide,”J. Hypertens Suppl. 14(5):S105-110 (Dec. 1996)Abstract Only.
Kapas et al., “Regulation of PAMP and adrenomedullin receptor expression in the rat adrenal zona glomerulosa”Endoc Res. 24(3-4):717-20 (Aug.-Nov. 1998)Abstract Only.
Kitamura et al., “Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma,”Biochem Biophys Res Commun192(2):553-560 (Apr. 30, 1993).
Kitamura et al., “Cloning and characterization of cDNA encoding a precursor for human adrenomedullin,”Biochem Biophys Res Commun194(2):720-725 (Jul. 30, 1993)Abstract Only.
Kitamura et al., “Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP),”FEBS Letters351(1):35-7 (Aug. 29, 1994)Abstract Only.
Kleiner and Stetler-Stevenson, “Matrix metalloproteinases and metastasis,”Cancer Chemother Pharmacol43(Suppl):S42-S51 (1999).
Kugler, “Matrix Metalloproteinases and their Inhibitors,”Anticancer Research19:1589-1592 (1999).
Kuwasako et al., “Increased plasma proadrenomedullin N-terminal 20 peptide in patients with essential hypertension,”Ann Clin Biochem. 36:(pt5):622-628 (Sep. 1999)Abstract Only.
Lewis et al., “Degradation of human adrenomedullin (1-52) by plasma membrane enzymes and identification of metabolites,”Peptides18(5):733-739 (1997).
Lisy et al., “Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin,”Am. J. Physiol. 275:F410-F414 (1998).
Makino et al., “Attenuated hypotensive response to proadrenomedullin N-terminal 20 peptide in pregnant rats: modulation by steroid hormones,”Peptides20(12):1521-1525 (1999)Abstract Only.
Martínez et al. “The Effects of Adrenomedulling Overexpression in Breast Tumor Cells,”J. Nat. Cancer Inst. 94(16):12 pages (Aug. 21, 2002).
Martínez et al., “Proadrenomedullin NH2-Terminal 20 Peptide is a Potent Angiogenic Factor, and its Inhibition Results in Reduction of Tumor Growth,”Cancer Res64:6489-6496 (Sep. 15, 2004).
Matsui et al., “Biosynthesis and Secretion of Adrenomedullin and Proadrenomedullin N-Terminal 20 Peptide in a Rat Model of Endotoxin Shock,”Hypertens24:543-549 (2001).
Matsui et al., “Lack of hypotensive effect of chronically infused proadrenomedullin N-terminal 20 peptide in rats,”Horm Metab Res30(9):555-6 (1998)Abstract Only.
Moody et al., “Adrenomedullin binds with high affinity, elevates cyclic AMP, and stimulates c-fos mRNA in C6 glioma cells,”Peptides18(8):1111-1115 (1997)Abstract Only.
Nakamura et al. “Comparison of vasodilator potency of adrenomedullin and proadrenomedullin N-terminal 20 peptide in human,”Life Sci. 65(20):2151-2156 (1999)Abstract Only.
Nossaman et al., “Effects of Phentolamine on Responses to PAMP in the Hindquarters Vascular Bed of the Rat,”J. Cardiovasc. Pharmacol Ther. 2(3):153-157 (Jul. 1997)Abstract Only.
Robert et al., “Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart,”Lab Invest. 76(5):729-738 (May 1997)Abstract Only.
Saita et al., “Cardiovascular and sympathetic effects of proadrenomedullin NH2-terminal 20 peptide in conscious rats,”Regul Pept77(1-3):147-153 (Oct. 16, 1998)Abstract Only.
Samson et al., “Central mechanisms for the hypertensive effects of preproadrenomedullin-derived peptides in conscious rats,”Am J. Physiol274:R1505-R1509 (1998).
Samson, “Proadrenomedullin-derived peptides,”Front Neuroendocrinol. 19(2):100-27 (Apr. 1998)Abstract Only.
Shimosawa and Fujito, “Hypotensive Effect of a Newly Identified Peptide, Proadrenomedullin N-Terminal 20 Peptide,”Hypertension28:325-329 (1996).
Shimosawa et al., “A Newly Identified Peptide, Proadrenomedullin N-Terminal 20 Peptide, Induces Hypotensive Action via Pertussis Toxin-Sensitive Mechanisms,”Hypertension30:1009-1014 (1997).
Shimosawa et al., “Adrenomedullin, an Endogenous Peptide, Counteracts Cardiovascular Damage,”Circulation105:106-111 (2002).
Uemura et al., “Aldosterone augments adrenomedullin production without stimulating pro-adrenomedullin N-termin
Cuttitta Frank
Martinez Alfredo
Stetler-Stevenson William G.
Klarquist Sparkman LLP.
Saoud Christine J
The United States of America as represented by the Department of
LandOfFree
Methods for inhibiting angiogenesis with inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting angiogenesis with inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting angiogenesis with inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2621506